据悉，截至预案公告日，国际实业实际控制人为冯现啁。冯现啁通过新疆融能间接持有公司1.1亿股， 占公司股权比例22.82%。按照发行数量上限1.44亿股计算，发行后公司总股本为6.25亿股，实际控制人 冯现啁通过新疆融能间接持有公司2.54亿股，占公司股权比例为40.63%。新疆融能仍为公司控股股东， 冯现啁先生仍为公司实际控制人，故本次发行股票不会导致公司控制权发生变化。 北京商报讯（记者 马换换 王蔓蕾）9月25日，国际实业（000159）披露公告称，公司拟向特定对象发行 股票募集资金总额不超过6.62亿元（含本数），扣除发行费用后，拟将募集资金净额全部用于补充流动 资金。本次发行的发行对象为公司控股股东新疆融能，发行对象以现金方式认购本次发行的全部股票。 公告显示，近年来，国际实业为了满足业务发展的资金需求，除通过经营活动补充流动资金外，还通过 银行借款等间接融资方式筹集资金。本次募集资金补充流动资金后，将有效满足公司经营规模扩大所带 来的新增营运资金需求，缓解公司资金需求压力，提高公司的抗风险能力、财务安全水平和财务灵活 性。 ...

南方财经9月25日电，国际实业(000159.SZ)9月25日公告，拟向控股股东新疆融能定向增发不超过1.44亿 股股票，募集资金不超过6.62亿元全部用于补充流动资金。本次定增旨在优化资本结构、降低财务风 险，并满足主营业务扩张带来的营运资金需求。公司近年来盈利呈现波动，2022年至2024年归母净利润 分别为2.98亿元、0.81亿元和-4.39亿元，经营性现金流对业务发展的支撑力度存在一定压力。最近三年 公司未进行现金分红，主要因盈利变化及重大资金支出安排。 ...

Core Viewpoint - Huizhou Zhongjing Electronics Technology Co., Ltd. plans to issue A-shares to specific investors, aiming to raise up to 700 million yuan for various projects, including a PCB production base in Thailand and upgrades to existing production lines [1][3]. Group 1: Fundraising and Investment Plans - The company intends to issue shares to no more than 35 specific investors, with the actual controller Yang Lin planning to subscribe for at least 70 million yuan, accounting for no more than 30% of the total shares issued [3]. - The total amount to be raised from this issuance is capped at 700 million yuan, with 300 million yuan allocated for the Thailand PCB intelligent production base project, 200 million yuan for production line upgrades in Huizhou, and 200 million yuan for working capital [3]. Group 2: Financial Performance - The company has faced poor financial performance, reporting net losses for three consecutive years from 2022 to 2024, with losses of 179 million yuan, 137 million yuan, and 87 million yuan respectively [4]. - In the first half of this year, the company achieved revenue of approximately 1.618 billion yuan, a year-on-year increase of 21.29%, and turned a profit with a net profit of approximately 18.29 million yuan, compared to a loss of 12 million yuan in the same period last year [4]. Group 3: Business Overview - Zhongjing Electronics specializes in the research, production, sales, and service of printed circuit boards (PCBs), with main products including rigid PCBs, high-density interconnect boards (HDI), flexible PCBs, rigid-flex boards, and flexible PCB assemblies [3].

Group 1 - The company International Industry (000159) plans to issue shares to specific investors in 2025, targeting its controlling shareholder Xinjiang Rongneng [1] - The total number of shares to be issued is not more than 144 million shares, with an issue price set at 4.59 yuan per share [1] - The total amount of funds raised from this issuance is expected to be no more than 662 million yuan, which will be used entirely to supplement working capital after deducting related issuance costs [1]

Core Viewpoint - International Industry (000159.SZ) plans to issue shares to specific investors, primarily to its controlling shareholder, Xinjiang Rongneng, to raise funds for working capital [1] Group 1 - The company intends to issue up to 144 million shares at a price of 4.59 yuan per share [1] - The total amount of funds raised from this issuance is expected to be no more than 662 million yuan, including the principal amount [1] - After deducting related issuance costs, all proceeds will be used to supplement working capital [1]

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. plans to raise up to 1.033 billion yuan through a private placement to Nanjing Haiqing Pharmaceutical Co., Ltd., which will result in Haiqing holding 20% of Mengke's shares and becoming its controlling shareholder [1] Group 1: Company Overview - Mengke Pharmaceutical focuses on the research and development of new drugs for infectious diseases, with its core product, Contizole, approved for market in China in 2021 [1] - Contizole generated sales revenues of 48.21 million yuan in 2022, 90.7764 million yuan in 2023, and is projected to reach 130 million yuan in 2024, with 66.97 million yuan in revenue for the first half of this year, reflecting a year-on-year growth of 10.26% [1] Group 2: Strategic Investment Rationale - The introduction of a strategic investor is aimed at alleviating pressure on sales channels and cash flow management, enhancing commercial efficiency without affecting the company's core business [1][2] - Mengke's CFO noted that the company’s existing team has limited coverage in hospitals, making it challenging to achieve explosive growth in the short term, thus necessitating external support for commercialization [2] Group 3: Financial Details and Market Reaction - The private placement price is set at 6.30 yuan per share, which is 80% of the average trading price over the previous 20 trading days, with a 36-month lock-up period for Haiqing's shares post-issuance [3] - Following the announcement, Mengke's stock price surged to a closing price of 9.71 yuan per share, indicating a positive market reaction to the news [3]

Group 1 - The company Shanghai Mankou Pharmaceutical Co., Ltd. plans to issue shares to specific investors, with the proposal approved by the board and supervisory committee on September 22, 2025 [1][3][27] - The issuance is subject to approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][27] - The company will hold its second extraordinary general meeting of shareholders on October 9, 2025, to discuss the share issuance and other related matters [4][5][8] Group 2 - The share issuance involves the subscription of 163,901,373 ordinary shares at a price of RMB 6.30 per share, totaling approximately RMB 1,032.58 million [30][32][33] - The shares will be locked for 36 months post-issuance, preventing transfer during this period [35][39] - The controlling shareholder after the issuance will be Nanjing Haiqing Pharmaceutical Co., Ltd., with a shareholding of 20% in Mankou Pharmaceutical [28][30] Group 3 - The company has committed to maintaining its independence in operations, assets, and finances post-transaction, ensuring no conflicts of interest arise [51][52][54] - There are no plans for significant changes to the company's main business or major asset disposals in the next 12 months [41][43] - The company has established measures to avoid any potential competition with its controlling shareholder's business [55]

新京报贝壳财经讯 9月22日，中京电子（002579）发布公告称，拟向特定对象发行股票募集资金总额不 超过7亿元，扣除发行费用后募集资金将全部用于泰国PCB智能化生产基地项目、惠州中京产线技改与 升级项目、补充流动资金。本次发行的发行对象为不超过35名（含本数）符合中国证监会规定条件的特 定对象，其中，公司实际控制人杨林拟认购金额不低于0.7亿元（含本数）且拟认购股票总数不超过本 次向特定对象发行股票总股数的30%（含本数）。 ...

Core Viewpoint - Zhongjing Electronics (002579.SZ) plans to raise up to 700 million yuan through a private placement of A-shares, with proceeds allocated to a PCB intelligent production base in Thailand, upgrades to production lines in Huizhou, and to supplement working capital [1][2]. Fundraising Projects - The total investment for the Thailand PCB intelligent production base project is 548.625 million yuan, with 300 million yuan expected to be funded from the raised capital [2]. - The Huizhou Zhongjing production line upgrade project has a total investment of 213.2249 million yuan, with 200 million yuan planned to be funded from the raised capital [2]. - The company plans to use 200 million yuan from the raised funds to supplement its working capital [2]. Issuance Details - The issuance will target no more than 35 specific investors, including the actual controller Yang Lin, who intends to subscribe for at least 70 million yuan, representing no more than 30% of the total shares issued [2][4]. - All investors will subscribe for shares in cash at the same price, with the pricing based on the average trading price of the company's shares over the 20 trading days prior to the issuance date [3]. - The maximum number of shares to be issued is 183,785,586, which does not exceed 30% of the company's total share capital prior to the issuance [3]. Control and Ownership - Yang Lin, the actual controller, holds 6.27% of the company's total shares directly and 19.06% through his controlled entity, totaling 25.33% of the voting rights [4]. - Post-issuance, Yang Lin's control over the company is expected to decrease to 21.79%, but he will remain the actual controller, ensuring no change in control [4].

格隆汇9月22日丨盟科药业(688373.SH)公布2025年度向特定对象发行股票预案，本次发行对象为南京海 鲸药业股份有限公司(称"海鲸药业"或"产业投资人")，发行对象以现金方式认购本次发行的股票，认购 金额不超过人民币10.33亿元(含本数)。本次向特定对象发行股票的募集资金总额不超过10.33亿元(含本 数)，全部用于公司日常研发与经营投入。 ...